Compliance review: Sun Pharma’s Halol plant gets 8 USFDA observations; company vows remedial steps after inspection
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Join our WhatsApp Community to receive travel deals, free stays, and special offers!
- Join Now -
Sun Pharmaceutical Industries faces scrutiny. The USFDA issued a Form 483. This follows an inspection of its Halol manufacturing plant in Gujarat. The inspection occurred between June 2 and June 13, 2025. Eight observations were noted regarding Good Manufacturing Practices. Sun Pharma is expected to respond. They will submit a remediation plan to address the concerns. What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
